Precise Biometrics AB

As of June 30, 2026, PRECISE BIOMETRICS carries a market capitalization of 25.57M, placing it among publicly traded companies globally. Its enterprise value stands at 24.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PRECISE BIOMETRICS's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, PRECISE BIOMETRICS has 174.85M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.95, and the price-to-book ratio stands at 2.15.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 24.74M versus a market cap of 25.57M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PRECISE BIOMETRICS maintains a current ratio of 0.93, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, PRECISE BIOMETRICS posted a negative return on equity (ROE) of -18.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.03, reflecting losses generated across the asset base. The company generates approximately 198,588.84 in revenue per employee across its workforce of 35.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 89.36 indicates how many times PRECISE BIOMETRICS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PRECISE BIOMETRICS recorded an income tax benefit of -35,894.35 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.40M and -2.37M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 6, 2026, PRECISE BIOMETRICS's stock has declined approximately 84.99% over the past 52 weeks. The 50-day moving average sits at 0.84, while the 200-day moving average is 1.04.

Over the twelve months ended June 30, 2026, PRECISE BIOMETRICS generated 7.10M in revenue and converted that into -2.37M in net income, yielding earnings per share of -0.03. EBITDA reached -2.47M, while operating income came in at -2.47M.

As of June 30, 2026, PRECISE BIOMETRICS holds 1.95M in cash and equivalents against 1.12M in total debt, resulting in a net debt position of -1.95M. Total book value stands at 11.89M, with working capital of -265,288.10 providing operational flexibility.

PRECISE BIOMETRICS produced 591,741.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.27M in capital expenditures, free cash flow totaled -673,844.16 - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, PRECISE BIOMETRICS posted a gross margin of 71.44, reflecting its pricing power and cost economics. The operating margin of -34.81 and net profit margin of -33.36 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.87: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.90, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PRECISE BIOMETRICS shareholders.

PRECISE BIOMETRICS's most recent stock split took place on July 24, 2026.